Specialty Pharma Journal Specialty, Precision & Technology
NEW YORK–(BUSINESS WIRE)–Bristol-Myers Squibb (NYSE:BMY) and Flatiron Health, a market leader in oncology-specific electronic health record software and the curation of regulatory-grade real-world data for cancer research and real-world evidence (RWE) generation, expanded their relationship today by announcing a three-year collaboration agreement. Bristol-Myers Squibb will use Flatiron’s real-world data to …
Tag Archives: HIT
May, 2018
-
1 May
Gilead and Verily Announce Scientific Collaboration to Identify and Understand Immunological and Molecular Drivers of Inflammatory Diseases
FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) and Verily Life Sciences LLC, an Alphabet company, today announced a scientific collaboration using Verily’s Immunoscape platform to identify and better understand the immunological basis of three common and serious inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease …
December, 2017
-
21 December
Accenture and Roche Collaborate to Enhance Digital Healthcare for Cancer Patients
NEW YORK–(BUSINESS WIRE)–Accenture (NYSE: ACN) today announced a collaborative services agreement with Roche. Under the terms of this exclusive multi-year agreement, Accenture will provide digital data integration services to Roche’s NAVIFY Tumor Board solution. A tumor board is a meeting in which multi-disciplinary healthcare teams review and discuss individual cancer …
November, 2017
-
20 November
Boehringer Ingelheim Launches New Platform Offering Open Access to Many of its Best Molecules to Unlock Their Full Potential
INGELHEIM, Germany–(BUSINESS WIRE)–Boehringer Ingelheim today announced the launch of opnME.com, a new platform offering free and open access to selected pre-clinical molecules for non-clinical investigation to scientists worldwide. Through opnME.com, molecules for some of the most relevant targets in biomedical research are shared, thereby creating possibilities for further independent and …
September, 2017
-
29 September
FDA Improves Access to Reports of Adverse Drug Reactions
The U.S. Food and Drug Administration today launched a new user-friendly search tool that improves access to data on adverse events associated with drug and biologic products through the FDA’s Adverse Event Reporting System (FAERS). The tool is designed to make it easier for consumers, providers, and researchers to access this …
April, 2017
-
21 April
H3 Biomedicine Extends Collaboration with Foundation Medicine to Develop Precision Therapies for Cancer
CAMBRIDGE, Mass.–(BUSINESS WIRE)–H3 Biomedicine Inc., a clinical stage biopharmaceutical company specializing in the discovery and development of precision medicines for oncology and a member of Eisai’s global Oncology Business Group, today announced that is has extended its multi-year collaboration with Foundation Medicine, Inc. for the discovery and development of precision …
March, 2017
-
24 March
Regeneron, UK Biobank and GSK Enter Gene Sequencing Initiative
TARRYTOWN, N.Y., March 22, 2017 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today announced a major research initiative among the Regeneron Genetics Center (RGC), U.K. Biobank and GSK to generate genetic sequence data from the 500,000 volunteer participants in the U.K. Biobank resource. The initiative will enable researchers to gain …
February, 2017
-
1 February
Big Data Brings Breast Cancer Research Forwards by ‘Decades’
Scientists have created a ‘map’ linking the shape of breast cancer cells to genes turned on and off, and matched it to real disease outcomes, which could one day help doctors select treatments, according to a study published in Genome Research today (Wednesday).* In a revolutionary new approach, Cancer Research …
January, 2017
-
16 January
10x Genomics Announces Publication of Study Demonstrating Single Cell Profiling in Leukemia Patients
PLEASANTON, Calif.–(BUSINESS WIRE)–10x Genomics, Inc., a company focused on enabling the mastery of biology by accelerating genomic discovery, today announced the publication of a study enabled by the company’s Chromium™ Single Cell 3’ Solution. This powerful new technology provides robust single-cell expression measurements, allowing the discovery of gene expression dynamics …
March, 2016
-
16 March
Sanofi Enters $2.3 Billion Deal with DiCE Molecules
Paris, France and San Francisco – March 16, 2016 – Sanofi and DiCE Molecules, a newly-launched, privately held company developing a next generation approach to small molecule drug discovery, today announced a five-year global collaboration to discover potential new therapeutics for up to 12 targets that encompass all disease areas …